

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

VOLUNTARY ANNOUNCEMENT
ENTERING PHASE III CLINICAL TRIAL OF QX004N AND
PAYMENT RECEIVED FROM HANSOHI PHARMA

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of an update on the latest business developments of the Company.

The Company is developing QX004N, an interleukin-23 subunit p19 (“**IL-23p19**”) inhibitor, for psoriasis (“**Ps**”) and Crohn’s disease (“**CD**”). In April 2024, the Company entered into an exclusive outlicensing agreement with Hansoh (Shanghai) Healthtech Co., Ltd.* (翰森(上海)健康科技有限公司), a wholly-owned subsidiary of Hansoh Pharmaceutical Group Company Limited (“**Hansoh Pharma**”, 翰森製藥集團有限公司, stock code: 3692.HK) for the research and development, manufacturing, and commercialization of QX004N within mainland China, Taiwan, Hong Kong and Macau (the “**License Agreement**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that QX004N recently has entered Phase III clinical trial, being the fourth product in the Company’s pipeline to be successfully advanced to Phase III stage.

Recently, the Company has received payments of RMB58.0 million from Hansoh Pharma according to the License Agreement, for reaching Phase III milestone of Ps and other payment terms.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, August 5, 2025

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.

* for identification purpose only